Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis.

[1]  M. Budoff,et al.  Pericardial, But Not Hepatic, Fat by CT Is Associated With CV Outcomes and Structure: The Multi-Ethnic Study of Atherosclerosis. , 2017, JACC. Cardiovascular imaging.

[2]  A. Lonardo,et al.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV , 2016, World journal of gastroenterology.

[3]  A. Lonardo,et al.  International Journal of Molecular Sciences Type 2 Diabetes in Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—liver: the " Musketeer " in the Spotlight , 2022 .

[4]  C. Frei,et al.  Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults , 2015, Journal of General Internal Medicine.

[5]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[6]  James G Terry,et al.  Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis , 2014, European journal of preventive cardiology.

[7]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[8]  Michael J Blaha,et al.  Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). , 2014, Journal of the American College of Cardiology.

[9]  Michael J Pencina,et al.  Application of new cholesterol guidelines to a population-based sample. , 2014, The New England journal of medicine.

[10]  M. Budoff,et al.  Relation of nonalcoholic fatty liver disease to the metabolic syndrome: the Multi-Ethnic Study of Atherosclerosis. , 2013, Journal of cardiovascular computed tomography.

[11]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[12]  Dong Li,et al.  Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. , 2012, Academic radiology.

[13]  P. Toth.  Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[14]  Moyses Szklo,et al.  Liver Attenuation, Pericardial Adipose Tissue, Obesity, and Insulin Resistance: The Multi‐Ethnic Study of Atherosclerosis (MESA) , 2011, Obesity.

[15]  J. J. Rivera,et al.  Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study , 2011, The Lancet.

[16]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[17]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[18]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Journal of the American College of Cardiology.

[19]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[20]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[21]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[22]  Jeffrey L. Anderson,et al.  ACCF / AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults , 2010 .

[23]  S. Sookoian,et al.  Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. , 2008, Journal of hepatology.

[24]  Fritz Schick,et al.  Identification and characterization of metabolically benign obesity in humans. , 2008, Archives of internal medicine.

[25]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[26]  Norbert Stefan,et al.  Causes and metabolic consequences of Fatty liver. , 2008, Endocrine reviews.

[27]  A. Kotronen,et al.  Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome , 2007, Diabetologia.

[28]  K. Pietiläinen,et al.  Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[29]  Ralph B D'Agostino,et al.  Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. , 2007, Archives of internal medicine.

[30]  G. Targher.  Non‐alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[31]  Zamir Halpern,et al.  Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[32]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[33]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[34]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[35]  James Sayre,et al.  Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. , 2004, Radiology.

[36]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[37]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[38]  L Dalla Palma,et al.  Noninvasive in vivo quantitative assessment of fat content in human liver. , 1997, Journal of hepatology.

[39]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.